Ana Del Campo García
Publications by Year
Research Areas
Biosimilars and Bioanalytical Methods, Pharmacogenetics and Drug Metabolism, Pancreatitis Pathology and Treatment, Colorectal Cancer Treatments and Studies, Amyloidosis: Diagnosis, Treatment, Outcomes
Most-Cited Works
- → Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial(2018)61 cited
- → Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach(2018)36 cited
- → Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)(2021)27 cited
- → Bioequivalence evaluation of two brands of meloxicam tablets (promotion® and mobicox®): pharmacokinetics in a healthy female Mexican population(2005)14 cited
- → A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers(2021)11 cited
- → Correlation of the Renal Cortex Volume With the Glomerular Filtration Rate in Live Donors for Renal Transplantation(2018)4 cited
- → Bioequivalence of 250 mg lysine clonixinate tablets after a single oral dose in a healthy female Mexican population under fasting conditions(2010)4 cited
- → Ictericia colestásica y síndrome constitucional como debut de una amiloidosis sistémica primaria(2003)2 cited
- → Rabdomiosarcoma paratesticular: a propósito de un caso en el adulto(2005)1 cited
- → Comparing the Accuracy of Standard Equations to Predict Glomerular Filtration Rate for Persons with Spinal Cord Injury: Which Is the “Best Fit?”(2024)1 cited